Wenger Vieli advised the Swiss startup specializing in AI risk management, Calvin Risk on all legal aspects of their recent seed funding round. Calvin Risk secured USD 4 million in funding in an operation led by Join Capital and seed + speed Ventures. This funding round will enable Calvin Risk to accelerate product development, scale its […]
Walder Wyss advised Swiss Life Holding on the repurchase of its own registered shares up to a maximum repurchase value of CHF 750 million. The repurchase will be followed by a capital reduction. The share buyback
Borel & Barbey has advised NeuroGyn in a successful CHF 3 million financing round led by a business angel. The Swiss medtech company specializing in neurotechnology solutions founded by Prof. Dr. Marc Possover focuses on improving
Kellerhals Carrard advised Schuman Financial on the closing of a €7 million seed round, led by RockawayX, with participation of Lightspeed Faction, Kraken Ventures, Nexo Ventures, GnosisVC, Delta Blockchain Fund, and Bankless Ventures. The team The
Homburger advised EQT, leader of the SwissCo consortium, in the transaction. Meanwhile, Niederer Kraft Frey represented the banking syndicate consisting of Citi, Goldman Sachs, Jefferies, Morgan Stanley, and UBS. SwissCo, together with the Abu Dhabi
Advestra has advised Viseca Payment Services in the placemento of CHF 150 million of 1.350% senior bonds, due 2029. The placement was supported by Raiffeisen Schweiz Genossenschaft, UBS, and Zürcher Kantonalbank,
Vischer advised Ikerian, a healthcare software platform company, on its first round of USD 8m Series B financing to advance its AI platform. The Series B financing round is led by strategic investor Sanoptis led
Lenz & Staehelin acted as Swiss counsel for GAM Holding, a publicly listed company on the SIX Swiss Exchange. GAM projected a capital increase and rights offering was completed as planned. Net proceeds from the
The Kellenberger family has significantly reduced its ownership in Calida Holding through two key transactions: a public buy-back offer and a direct share repurchase. Homburger served as legal advisor to the Kellenberger family, guiding them
On October 25, 2024, Homburger advised Molecular Partners, a clinical-stage biotechnology company, in the announcement of the pricing of an underwritten public offering. The offering consisted of 3,642,988 American Depositary Shares (ADSs), representing new shares, priced at $5.49 per
